REGULATORY

Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More

February 27, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese health ministry on February 24 approved label expansions for a batch of medicines including a pediatric indication for Pfizer’s sedative agent Precedex (dexmedetomidine). An α2 agonist, Precedex is now approved for sedation during non-invasive procedures and tests in…

To read the full story

Label Expansions for Nubeqa, Rinvoq, Imbruvica Now in Line for Approval
February 2, 2023
Semaglutide in Line for March Approval as Obesity Drug, Precedex Too
January 30, 2023

REGULATORY

Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…